Atrion (NASDAQ:ATRI) Rating Lowered to Strong Sell at BidaskClub

Atrion (NASDAQ:ATRI) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Tuesday, January 9th.

Atrion (NASDAQ ATRI) traded down $17.40 during trading hours on Tuesday, hitting $550.10. The company’s stock had a trading volume of 8,185 shares, compared to its average volume of 3,634. The firm has a market cap of $1,018.68, a price-to-earnings ratio of 30.48 and a beta of 0.73. Atrion has a 52-week low of $459.05 and a 52-week high of $694.00.

Atrion (NASDAQ:ATRI) last posted its quarterly earnings results on Wednesday, November 8th. The medical instruments supplier reported $4.29 earnings per share for the quarter. The firm had revenue of $37.90 million for the quarter. Atrion had a return on equity of 18.23% and a net margin of 21.03%.

Several large investors have recently bought and sold shares of the business. Neuberger Berman Group LLC increased its position in shares of Atrion by 4.0% during the 3rd quarter. Neuberger Berman Group LLC now owns 86,185 shares of the medical instruments supplier’s stock worth $57,916,000 after purchasing an additional 3,291 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Atrion by 2.2% during the 2nd quarter. Vanguard Group Inc. now owns 79,246 shares of the medical instruments supplier’s stock worth $50,979,000 after acquiring an additional 1,676 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Atrion by 1.6% during the 3rd quarter. Dimensional Fund Advisors LP now owns 64,290 shares of the medical instruments supplier’s stock worth $43,203,000 after acquiring an additional 1,022 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Atrion by 46.3% during the 2nd quarter. Renaissance Technologies LLC now owns 58,834 shares of the medical instruments supplier’s stock worth $37,848,000 after acquiring an additional 18,633 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Atrion by 3.0% during the 2nd quarter. State Street Corp now owns 31,790 shares of the medical instruments supplier’s stock worth $20,446,000 after acquiring an additional 919 shares during the last quarter. 59.06% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Atrion (NASDAQ:ATRI) Rating Lowered to Strong Sell at BidaskClub” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/04/bidaskclub-downgrades-atrion-atri-to-strong-sell.html.

Atrion Company Profile

Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply